Safety and Efficacy of Poly-L-Lactic Acid in HIV-Lipoatrophy and Lipoatrophy of Aging

February 2007 | Volume 6 | Issue 2 | Original Article | 123 | Copyright © 2007

C. William Hanke MD MPH FACP, Kelley Pagliai Redbord MD

Abstract

Background: Poly-L-lactic acid (PLLA) is an injectable filler used for the treatment of facial fat loss secondary to HIV and aging. The US FDA approved PLLA for the treatment of HIV lipoatrophy in August 2004. Observations: Sixty-five patients were treated with PLLA; 27 were HIV positive and 38 were HIV negative. The HIV patients had more severe facial lipoatrophy at presentation and improved more given their level of severity. The HIV positive patients required more treatment sessions and more PLLA to reach full correction than the non-HIV patients. Ninety-four percent of all patients had no complications and the effects of PLLA were similar in both groups. All complications were temporary and resolved over time. Patient satisfaction metrics indicated that all patients were “very satisfied” with their treatment. The HIV lipoatrophy patients indicated marked quality of life improvement. Conclusions: PLLA is a safe, efficacious, and satisfying treatment for facial fat loss associated with HIV and aging.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

Related Articles